# Phase 2 Leukemia, Lymphocytic: 65 recruiting (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 65 trials in phase 2 for Leukemia, Lymphocytic, Chronic, B-Cell that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Leukemia, Lymphocytic, Chronic, B-Cell trials: 65 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/leukemia-lymphocytic-chronic-b-cell

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 65
- Recruiting or not yet: 65
- Read on: November 19, 2026

## Trials

The 25 newest of 65, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 21, 2026 | NCT07887061 | Tacabrutideg and Sonrotoclax, With Response-Guided Obinutuzumab, for the Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic... | Fred Hutchinson Cancer Center | Phase 2 | Not yet recruiting | Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07887061) |
| September 14, 2026 | NCT07819214 | Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKI | University of California, Irvine | Phase 2 | Not yet recruiting | CLL, CLL (Chronic Lymphocytic Leukemia), Chronic Lymphocytic Leukemia (CLL), BTKi | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07819214) |
| September 10, 2026 | NCT07812246 | Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 Trial | City of Hope Medical Center | Phase 2 | Not yet recruiting | Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07812246) |
| September 1, 2026 | NCT07796373 | Nemtabrutinib for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Leukemia (SLL) Refractory to Covalent Bruton Tyrosine Kinase... | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 | Not yet recruiting | Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07796373) |
| July 31, 2026 | NCT07739459 | Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) | The Lymphoma Academic Research Organisation | Phase 2 | Not yet recruiting | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 95 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07739459) |
| July 31, 2026 | NCT07738887 | Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations | The Lymphoma Academic Research Organisation | Phase 2 | Not yet recruiting | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07738887) |
| July 29, 2026 | NCT07734038 | Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma | Sponsor not shown (see the record) | Phase 2 | Recruiting | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 155 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07734038) |
| July 16, 2026 | NCT07709000 | A Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006) | Merck Sharp & Dohme LLC | Phase 2 | Recruiting | Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Hematologic Malignancies | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07709000) |
| July 8, 2026 | NCT07690891 | Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic Leukemia | Medical College of Wisconsin | Phase 2 | Not yet recruiting | Chronic Lymphocytic Leukemia | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07690891) |
| July 6, 2026 | NCT07685717 | Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia | Sponsor not shown (see the record) | Phase 2 | Recruiting | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07685717) |
| July 2, 2026 | NCT07682415 | Zanubrutinib Induction Followed by Delayed Fixed-Duration Combination With Sonrotoclax for CLL/SLL：Stop Trial 2.0 | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | CLL / SLL | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07682415) |
| June 30, 2026 | NCT07674810 | A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Naïve Chronic Lymphocytic... | M.D. Anderson Cancer Center | Phase 2 | Not yet recruiting | Chronic Lymphocytic Leukemia | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07674810) |
| May 27, 2026 | NCT07609823 | A Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL | Guangzhou Lupeng Pharmaceutical Company LTD. | Phase 2 | Recruiting | Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07609823) |
| May 12, 2026 | NCT07582159 | Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | City of Hope Medical Center | Phase 2 | Recruiting | Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07582159) |
| April 29, 2026 | NCT07557056 | Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Sponsor not shown (see the record) | Phase 2 | Recruiting | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07557056) |
| April 13, 2026 | NCT07526597 | Study on Treatment Outcome Patterns for Patients With CLL After Discontinuation of BTK Inhibitors | UNC Lineberger Comprehensive Cancer Center | Phase 2 | Not yet recruiting | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07526597) |
| April 3, 2026 | NCT07508995 | A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With... | M.D. Anderson Cancer Center | Phase 2 | Recruiting | Chronic Lymphocytic Leukemia (CLL) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07508995) |
| December 9, 2025 | NCT07271667 | A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and... | Curis, Inc. | Phase 2 | Recruiting | Chronic Lymphocytic Leukemia, B-cell Malignancies | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07271667) |
| October 28, 2025 | NCT07221500 | A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor... | Nurix Therapeutics, Inc. | Phase 2 | Recruiting | Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07221500) |
| October 20, 2025 | NCT07218510 | Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic... | City of Hope Medical Center | Phase 2 | Recruiting | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07218510) |
| September 26, 2025 | NCT07194980 | Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Fred Hutchinson Cancer Center | Phase 2 | Recruiting | Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small... | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07194980) |
| September 4, 2025 | NCT07154264 | A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10) | Dizal Pharmaceuticals | Phase 2 | Recruiting | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07154264) |
| August 7, 2025 | NCT07108998 | Study of Epcoritamab as a Consolidation Therapy in CLL/SLL | Sponsor not shown (see the record) | Phase 2 | Recruiting | CLL/SLL, CLL, SLL, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma Variant... | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07108998) |
| July 14, 2025 | NCT07061951 | Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia | National Cancer Institute (NCI) | Phase 2 | Recruiting | Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia... | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07061951) |
| June 17, 2025 | NCT07024706 | MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without... | AstraZeneca | Phase 2 | Recruiting | Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07024706) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Fred Hutchinson Cancer Center | 5 |
| M.D. Anderson Cancer Center | 4 |
| City of Hope Medical Center | 4 |
| Masonic Cancer Center, University of Minnesota | 2 |
| The Lymphoma Academic Research Organisation | 2 |
| University of Utah | 2 |
| Institute of Hematology & Blood Diseases Hospital, China | 2 |
| National Heart, Lung, and Blood Institute (NHLBI) | 2 |
| [Dizal Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/dizal-pharmaceuticals) | 2 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 1 |
| University of California, Irvine | 1 |
| The First Affiliated Hospital with Nanjing Medical University | 1 |
| Gruppo Italiano Malattie EMatologiche dell'Adulto | 1 |
| Massachusetts General Hospital | 1 |
| National Cancer Institute (NCI) | 1 |
| Ohio State University Comprehensive Cancer Center | 1 |
| VA Office of Research and Development | 1 |
| Loxo Oncology, Inc. | 1 |
| Medical College of Wisconsin | 1 |
| Nurix Therapeutics, Inc. | 1 |
| Guangzhou Lupeng Pharmaceutical Company LTD. | 1 |
| University Hospital, Clermont-Ferrand | 1 |
| UNC Lineberger Comprehensive Cancer Center | 1 |
| Peter MacCallum Cancer Centre, Australia | 1 |
| Roswell Park Cancer Institute | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 46 |
| Italy | 8 |
| China | 8 |
| Spain | 6 |
| France | 5 |
| United Kingdom | 4 |
| Australia | 3 |
| Poland | 3 |
| Austria | 2 |
| Brazil | 2 |
| Germany | 2 |
| Israel | 2 |
| Romania | 2 |
| Belgium | 2 |
| Canada | 2 |
| Czechia | 2 |
| Bulgaria | 1 |
| Denmark | 1 |
| Greece | 1 |
| Hungary | 1 |
| Slovakia | 1 |
| South Korea | 1 |
| Turkey (Türkiye) | 1 |
| Ireland | 1 |
| Colombia | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Real estate firms in the United States](https://specstream.ai/data/businesses/real-estate-firms/united-states)
- [Community health centers in the United States](https://specstream.ai/data/businesses/community-health-centers/united-states)
- [Pediatric anesthesiology practices in the United States](https://specstream.ai/data/businesses/pediatric-anesthesiology-practices/united-states)
- [Boat and ship manufacturers in the United States](https://specstream.ai/data/businesses/boat-and-ship-manufacturers/united-states)
- [Medical billing companies in the United States](https://specstream.ai/data/businesses/medical-billing-companies/united-states)
- [Asian restaurants in the United States](https://specstream.ai/data/businesses/asian-restaurants/united-states)
